Cart
sales@molnova.com
Cetuximab (anti-EGFR)
CAS No. 205923-56-4
Cetuximab (anti-EGFR)( C225 )
Catalog No. M21142 CAS No. 205923-56-4
Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 260 | In Stock |
|
| 5MG | 434 | In Stock |
|
| 10MG | 627 | In Stock |
|
| 25MG | 981 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCetuximab (anti-EGFR)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
DescriptionCetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
In Vitro——
-
In Vivo——
-
SynonymsC225
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Areacancer
-
IndicationColorectal Cancer
Chemical Information
-
CAS Number205923-56-4
-
Formula Weight2756.23
-
Molecular FormulaC107H179N35O36S7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Huang S M Bock J M Harari P M . Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation Apoptosis and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck1[J]. Cancer Res 1999 59(8):1935-1940.
molnova catalog
related products
-
Lumretuzumab
Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity for the study of advanced HER3-positive solid tumors and breast cancer.
-
Pyrotinib maleate
Pyrotinib maleate (SHR-1258 maleate)?is a potent and selective EGFR/HER2 dual inhibitor with IC50 of 13/38 nM, respectively.
-
CHMFL-EGFR-202
CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).
